The Enara program was founded on years of research and clinical studies.
The research studying the effects of the Enara program and methods have shown significant evidence in the improvement of health outcomes related to obesity and type 2 diabetes.
Data for 233 patients enrolled in this precision medicine weight loss program were analyzed. Patients at 3, 6, and 12 months lost on average 11.99% , 13.87%, and 11.16% of baseline weight, respectively.
At week 72, AOM users (N = 71) achieved significantly greater mean percentage reduction in baseline weight than non‐users (N = 58). On average, baseline weight decreased by 14.04 ± 6.2% in users versus 10.9 ± 6.8% in non‐users (P = 0.008); 84% and 94% of non‐user and AOM users lost >5% weight loss (P = 0.006).
"Recent guidelines generally recommend anti‐obesity medications (AOMs) only for patients who have failed to achieve 5% weight loss through dietary, exercise and/or lifestyle modification interventions alone 1-5. However, the optimal time to introduce an AOM in the setting of a comprehensive weight loss programme has not been well studied..."
"Our study demonstrated that all patients who participated in this hybrid digital and in-person weight loss program lost >11% of their baseline weight across multiple time points. Leveraging the real-time connectivity, tailored elements, and engagement of a mobile app may benefit weight loss programs."
"Participants in the Enara Health precision weight loss program lost an average of -13.99% at 18 months. Self tracking and increased provider-patient touch points characterized high achievers at 18 months. Mobile health applications may be better suited to achieve sustained weight loss by designing features that facilitate provider-patient interactions on top of self tracking technology."
"This retrospective study aimed to evaluate the impact of Anti‐Obesity Medication (AOM) initiation, usage and duration on weight loss in a 72‐week precision obesity program. The type of AOM, diet and exercise plan was chosen based upon an individual's biological and psychosocial needs. The 72‐week study duration allowed for a fair investigation of the downstream impact of delayed vs early AOM initiation "
Company
Partner with us
Testing Locations
California | 3050 S Delaware St, San Mateo, CA 94403
Texas | 6155 Sports Village Rd Suite 200, Frisco, TX 75033
Illinois | 16501 106th Court
Orland Park, Illinois 60467